Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The investigators intend to perform exploratory evaluation of the treatment effectiveness and
safety of PM012 Tablet of PuriMED Co., Ltd. at 2 doses in Korean patients with mild to
moderate dementia of Alzheimer's type. To achieve this, this study aims to compare each dose
with placebo control for the efficacy and safety to explore the clinically optimal dose of
PM012 Tablet for therapeutic confirmatory (phase 3) clinical studies.